vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $71.1M, roughly 1.3× RE/MAX Holdings, Inc.). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 2.0%, a 26.4% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $32.6M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs -4.7%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
DVAX vs RMAX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $71.1M |
| Net Profit | $26.9M | $1.4M |
| Gross Margin | — | — |
| Operating Margin | 22.4% | 13.1% |
| Net Margin | 28.4% | 2.0% |
| Revenue YoY | 17.7% | -1.8% |
| Net Profit YoY | 53.0% | -75.2% |
| EPS (diluted) | $0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $71.1M | ||
| Q3 25 | $94.9M | $73.2M | ||
| Q2 25 | $95.4M | $72.8M | ||
| Q1 25 | $68.2M | $74.5M | ||
| Q4 24 | $72.0M | $72.5M | ||
| Q3 24 | $80.6M | $78.5M | ||
| Q2 24 | $73.8M | $78.5M | ||
| Q1 24 | $50.8M | $78.3M |
| Q4 25 | — | $1.4M | ||
| Q3 25 | $26.9M | $4.0M | ||
| Q2 25 | $18.7M | $4.7M | ||
| Q1 25 | $-96.1M | $-2.0M | ||
| Q4 24 | $7.0M | $5.8M | ||
| Q3 24 | $17.6M | $966.0K | ||
| Q2 24 | $11.4M | $3.7M | ||
| Q1 24 | $-8.7M | $-3.4M |
| Q4 25 | — | 13.1% | ||
| Q3 25 | 22.4% | 25.0% | ||
| Q2 25 | 15.1% | 19.3% | ||
| Q1 25 | -34.7% | 7.2% | ||
| Q4 24 | -2.3% | 5.9% | ||
| Q3 24 | 12.5% | 19.4% | ||
| Q2 24 | 7.0% | 20.6% | ||
| Q1 24 | -35.0% | 5.8% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | 28.4% | 5.4% | ||
| Q2 25 | 19.6% | 6.4% | ||
| Q1 25 | -141.0% | -2.6% | ||
| Q4 24 | 9.8% | 8.0% | ||
| Q3 24 | 21.8% | 1.2% | ||
| Q2 24 | 15.4% | 4.7% | ||
| Q1 24 | -17.2% | -4.3% |
| Q4 25 | — | — | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.12 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $534.1M | $452.4M |
| Total Assets | $946.5M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $118.7M | ||
| Q3 25 | $160.2M | $107.5M | ||
| Q2 25 | $99.1M | $94.3M | ||
| Q1 25 | $51.7M | $89.1M | ||
| Q4 24 | $95.9M | $96.6M | ||
| Q3 24 | $119.3M | $83.8M | ||
| Q2 24 | $112.5M | $66.1M | ||
| Q1 24 | $132.0M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | — | $452.4M | ||
| Q3 25 | $534.1M | $448.1M | ||
| Q2 25 | $494.2M | $442.4M | ||
| Q1 25 | $530.9M | $433.5M | ||
| Q4 24 | $596.8M | $429.5M | ||
| Q3 24 | $681.4M | $423.1M | ||
| Q2 24 | $642.8M | $418.4M | ||
| Q1 24 | $618.5M | $412.0M |
| Q4 25 | — | $582.5M | ||
| Q3 25 | $946.5M | $582.2M | ||
| Q2 25 | $918.4M | $574.8M | ||
| Q1 25 | $945.9M | $571.4M | ||
| Q4 24 | $986.3M | $581.6M | ||
| Q3 24 | $1.1B | $578.6M | ||
| Q2 24 | $1.0B | $571.4M | ||
| Q1 24 | $986.6M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $40.9M |
| Free Cash FlowOCF − Capex | $32.6M | $33.5M |
| FCF MarginFCF / Revenue | 34.4% | 47.1% |
| Capex IntensityCapex / Revenue | 1.3% | 10.4% |
| Cash ConversionOCF / Net Profit | 1.26× | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.9M | ||
| Q3 25 | $33.8M | $17.7M | ||
| Q2 25 | $23.4M | $4.6M | ||
| Q1 25 | $-19.6M | $5.7M | ||
| Q4 24 | $53.0M | $59.7M | ||
| Q3 24 | $19.5M | $17.6M | ||
| Q2 24 | $10.7M | $15.9M | ||
| Q1 24 | $-16.7M | $9.4M |
| Q4 25 | — | $33.5M | ||
| Q3 25 | $32.6M | $16.4M | ||
| Q2 25 | $22.0M | $2.9M | ||
| Q1 25 | $-23.6M | $4.0M | ||
| Q4 24 | $49.5M | $53.0M | ||
| Q3 24 | $18.1M | $16.3M | ||
| Q2 24 | $9.9M | $14.0M | ||
| Q1 24 | $-17.4M | $6.8M |
| Q4 25 | — | 47.1% | ||
| Q3 25 | 34.4% | 22.4% | ||
| Q2 25 | 23.0% | 4.0% | ||
| Q1 25 | -34.6% | 5.3% | ||
| Q4 24 | 68.8% | 73.2% | ||
| Q3 24 | 22.5% | 20.8% | ||
| Q2 24 | 13.5% | 17.8% | ||
| Q1 24 | -34.3% | 8.6% |
| Q4 25 | — | 10.4% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 1.5% | 2.2% | ||
| Q1 25 | 5.8% | 2.3% | ||
| Q4 24 | 4.8% | 9.1% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 1.1% | 2.4% | ||
| Q1 24 | 1.5% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | 1.26× | 4.45× | ||
| Q2 25 | 1.25× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | 10.28× | ||
| Q3 24 | 1.11× | 18.22× | ||
| Q2 24 | 0.94× | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
